This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): ADX71149, mGluR2PAM
Description: ADX71149 is a metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM).
Deal Structure: In January 2005, Addex announced that it has entered an exclusive worldwide research collaboration and licence agreement with Ortho-McNeil Pharmaceutical, a Johnson & Johnson company, to discover, develop and commercialize novel compounds modulating allosterically G-Protein Coupled Receptors. The initial drug discovery research will be conducted both at Addex and at Johnson & Johnson Pharmaceutical Research and Development. Through a joint steering committee, Addex and J&JPRD will collaborate in all phases of research and development up to clinical proof of concept.
Under the terms of the agreement, Ortho-McNeil will pay Addex an upfront fee and research funding for 2 years. In addition, Addex will be eligible for payments on successful achievement of pre-specified scientific, clinical and regulatory milestones, and royalties on product sales.
In May 2010, Addex disclosed further terms of its partnership with Ortho-McNeil-Janssen Pharmaceuticals. Under the terms of the...See full deal structure in Biomedtracker
Partners: Addex Therapeutics
Additional information available to subscribers only: